CN105477251A - Pharmaceutic preparation for treating hypomenorrhea with pelvic inflammation - Google Patents
Pharmaceutic preparation for treating hypomenorrhea with pelvic inflammation Download PDFInfo
- Publication number
- CN105477251A CN105477251A CN201610045938.4A CN201610045938A CN105477251A CN 105477251 A CN105477251 A CN 105477251A CN 201610045938 A CN201610045938 A CN 201610045938A CN 105477251 A CN105477251 A CN 105477251A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- hypomenorrhea
- herba
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037093 Menstruation Disturbances Diseases 0.000 title claims abstract description 45
- 206010021033 Hypomenorrhoea Diseases 0.000 title claims abstract description 43
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 38
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- 244000295490 Salvia japonica Species 0.000 claims description 34
- 235000005794 Salvia japonica Nutrition 0.000 claims description 34
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 33
- 244000025254 Cannabis sativa Species 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 25
- 239000009636 Huang Qi Substances 0.000 claims description 23
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 23
- 239000010931 gold Substances 0.000 claims description 23
- 229910052737 gold Inorganic materials 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 18
- 241001150538 Iria Species 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 11
- 230000001476 alcoholic effect Effects 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000013049 sediment Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 3
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 229940068682 chewable tablet Drugs 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229940023488 pill Drugs 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 19
- 210000004369 blood Anatomy 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 16
- 230000017531 blood circulation Effects 0.000 abstract description 14
- 210000003734 kidney Anatomy 0.000 abstract description 11
- 210000000952 spleen Anatomy 0.000 abstract description 11
- 208000024891 symptom Diseases 0.000 abstract description 9
- 210000004185 liver Anatomy 0.000 abstract description 8
- 208000002193 Pain Diseases 0.000 abstract description 6
- 230000036407 pain Effects 0.000 abstract description 6
- 210000002784 stomach Anatomy 0.000 abstract description 5
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000018109 Cyperus longus Nutrition 0.000 abstract 1
- 244000150195 Cyperus longus Species 0.000 abstract 1
- 244000262912 Desmodium triflorum Species 0.000 abstract 1
- 235000011975 Desmodium triflorum Nutrition 0.000 abstract 1
- 241001269712 Laggera Species 0.000 abstract 1
- 241000522169 Lespedeza Species 0.000 abstract 1
- 241000122904 Mucuna Species 0.000 abstract 1
- 240000007594 Oryza sativa Species 0.000 abstract 1
- 235000007164 Oryza sativa Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000002912 Salvia officinalis Nutrition 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000009566 rice Nutrition 0.000 abstract 1
- 235000002020 sage Nutrition 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 description 25
- 241000700159 Rattus Species 0.000 description 20
- 230000005906 menstruation Effects 0.000 description 16
- 210000004291 uterus Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- 231100000614 poison Toxicity 0.000 description 11
- 208000019255 Menstrual disease Diseases 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 239000003440 toxic substance Substances 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 8
- 230000027758 ovulation cycle Effects 0.000 description 8
- 208000004880 Polyuria Diseases 0.000 description 7
- 230000035619 diuresis Effects 0.000 description 7
- 235000014347 soups Nutrition 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 208000005171 Dysmenorrhea Diseases 0.000 description 5
- 206010013935 Dysmenorrhoea Diseases 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000008736 traumatic injury Effects 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000002175 menstrual effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 206010017553 Furuncle Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 206010000210 abortion Diseases 0.000 description 3
- 231100000176 abortion Toxicity 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000004568 cement Substances 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000003821 menstrual periods Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 229960003742 phenol Drugs 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000715 Mucilage Polymers 0.000 description 2
- 206010067868 Skin mass Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 206010046901 vaginal discharge Diseases 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010034238 Pelvic adhesions Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010063146 Uterine hypoplasia Diseases 0.000 description 1
- 235000006085 Vigna mungo var mungo Nutrition 0.000 description 1
- 240000005616 Vigna mungo var. mungo Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940010073 hydrocortisone injection Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000545 luteal phase defect Toxicity 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 208000001581 lymphogranuloma venereum Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000009247 menarche Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 208000017942 premature ovarian failure 1 Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000011450 sequencing therapy Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicines and discloses a pharmaceutic preparation for treating hypomenorrhea with pelvic inflammation and a preparation method of the pharmaceutic preparation. The pharmaceutic preparation is prepared from the medicinal raw materials of desmodium triflorum, astragalus, radix acanthopanacis semticosi, caulis sargentodoxae, radix cynanchi, root of woolly lespedeza, evergreen mucuna, salvia officinalis, winged laggera herb and herb of rice galingale. The pharmaceutic preparation is comprehensive in legislation and considerate in medication, can play a miraculous role and take the effects of dispelling wind to eliminate dampness, activating blood circulation to remove stasis, clearing away heat and toxic materials and nourishing blood to dredge collaterals, also can nourish the liver and the kidney, strengthen the spleen and stomach and treat both symptoms and root causes, has a unique effect on patients with hypomenorrhea and pelvic inflammation, has less side effects, achieves relatively good compliance of the patients, is convenient to take, can effectively relieve the burden and pain of the patients and achieve the purpose of treating both symptoms and root causes and is worthy of wide popularization in clinic practice.
Description
Technical field
The invention belongs to the field of Chinese medicines, relate to the medicine for the treatment of menoxenia, particularly relate to a kind of hypomenorrhea for the treatment of and accompany pharmaceutical preparation of pelvic inflammatory disease and preparation method thereof.
Background technology
It is normal that hypomenorrhea refers to menstrual cycle, and be obviously less than in the past through measuring, and less than two days, or drop was namely clean, is referred to as " hypomenorrhea ".Ancient books is also known as " a small amount of menses and menstruating unsmoothly " " very few through measuring " etc.Generally think that menstruation is less than 20mL through blood volume and is hypomenorrhea.Hypomenorrhea is one of performance of menoxenia, and existing sickness rate is raising year by year.
" Plain Questions innocence in ancient times opinion " one is write: " woman's kidney qi is contained, the menarche, and conception vessel leads to, and taichong channel is contained, regular menstrual cycle." illustrate that menstruation is female normal physiological activity.Menstruation is monthly gone under normal circumstances, its menstrual period and blood volume and color, should be all normal through matter.The exception of menstruation, does not just show as merely gynaecopathia so simple, is often a reaction of whole body pathologic condition change yet.Hypomenorrhea is exactly one of performance of irregular menstruation.This symptom of hypomenorrhea is found in premature ovarian failure, polycystic ovarian syndrome, uterine hypoplasia, endometritis, artificial abortion operation etc. in western medicine.
Can be found by the clinical people coming to go to a doctor, hypomenorrhea has become a problem of the numerous women of puzzlement, the patient of many hypomenorrhea is when gynecologial examination, light or heavy can find with pelvic inflammation, but it is how not obvious, if do not treated, pelvic inflammation maybe can have influence on endometrium, by interior neural reflex, cause inner membrance to secrete bad, Estrogen and progestin imbalance or inner membrance in resting state, all can make inner membrance faulty restoration and not generating period change to gonadal hormone reaction, thus increase the weight of hypomenorrhea, also or prognosis recurrence.
At present, the medicine for the treatment of hypomenorrhea has Western medicine and the large class of Chinese medicine two, but this two classes medicine all can not prevent or treat pelvic inflammatory disease, and western medicine hypomenorrhea administration time is long, and side effect is large, curative effect is not thorough, not only easily cause gastrointestinal reaction, easily increase the weight of endocrine disturbance again, although and existing Chinese patent medicine preparation can treat female irregular menstruation, but offer limited effectiveness, and the pelvic inflammatory disease occurred together to hypomenorrhea is often invalid.And differentiation of tcm, often evident in efficacy.
Summary of the invention
In order to solve the problem, the present invention aims to provide a kind of hypomenorrhea for the treatment of and accompanies pharmaceutical preparation of pelvic inflammatory disease and preparation method thereof.
An object of the present invention is to provide a kind of pharmaceutical preparation for the treatment of hypomenorrhea companion pelvic inflammatory disease.
A kind of pharmaceutical preparation for the treatment of hypomenorrhea companion pelvic inflammatory disease provided by the invention is that medicinal raw material is made by 3 gold grass, the Radix Astragali, Radix Et Caulis Acanthopanacis Senticosi, Caulis Mucunae Wangii, Radix cynanchi wilfordii, Radix Lespedezae Tomentosae, Radix Seu Caulis Mucunae Sempervirentis, Salvia japonica Thunb., Herba Laggerae Alatae, Herba Cyperi Iriaes.In side, the weight of each medicinal raw material is as follows: 3 careless 15-25 parts of gold, Radix Astragali 5-15 part, Radix Et Caulis Acanthopanacis Senticosi 8-18 part, Caulis Mucunae Wangii 16-36 part, Radix cynanchi wilfordii 10-20 part, Radix Lespedezae Tomentosae 15-35 part, Radix Seu Caulis Mucunae Sempervirentis 18-36 part, Salvia japonica Thunb. 20-40 part, Herba Laggerae Alatae 15-25 part, Herba Cyperi Iriae 20-40 part.
Further preferably, treat a pharmaceutical preparation for hypomenorrhea companion pelvic inflammatory disease, it is characterized in that being made up of the medicinal raw material of following weight: 3 careless 17-23 parts of gold, Radix Astragali 8-13 part, Radix Et Caulis Acanthopanacis Senticosi 11-15 part, Caulis Mucunae Wangii 26-32 part, Radix cynanchi wilfordii 12-17 part, Radix Lespedezae Tomentosae 24-30 part, Radix Seu Caulis Mucunae Sempervirentis 20-26 part, Salvia japonica Thunb. 26-34 part, Herba Laggerae Alatae 18-23 part, Herba Cyperi Iriae 25-30 part.
Further preferably, treat a pharmaceutical preparation for hypomenorrhea companion pelvic inflammatory disease, it is characterized in that being made up of the medicinal raw material of following weight: 3 golden grass 20 parts, the Radix Astragali 12 parts, Radix Et Caulis Acanthopanacis Senticosi 12 parts, Caulis Mucunae Wangii 28 parts, Radix cynanchi wilfordii 15 parts, Radix Lespedezae Tomentosae 25 parts, Radix Seu Caulis Mucunae Sempervirentis 25 parts, Salvia japonica Thunb. 30 parts, Herba Laggerae Alatae 18 parts, Herba Cyperi Iriaes 26 parts.
Fang Zhong: Herba Laggerae Alatae is worked hard tepor, dispels the wind, dehumidifying, changes stagnant, dissipating blood stasis, detumescence, removing toxic substances; The pungent tepor of Herba Cyperi Iriae, expelling wind and removing dampness, promoting blood flow to regulate menstruation; Two medicine 5 expelling wind and removing dampness, promoting blood circulation to remove blood stasis, subduing swelling and detoxicating is monarch drug.The bitter temperature of Caulis Mucunae Wangii, bone and muscle strengthening, menstruation regulating blood nourishing medicinal; Radix cynanchi wilfordii sweetness and bitterness tepor, invigorating the liver and kidney, bone and muscle strengthening, strengthening the spleen and stomach, Radix Lespedezae Tomentosae is sweet light flat, spleen invigorating tonify deficiency, clearing away heat-damp and promoting diuresis, promoting blood flow to regulate menstruation; Radix Seu Caulis Mucunae Sempervirentis promoting blood flow to regulate menstruation, relaxing muscles and tendons of enriching blood, four medicines are ministerial drug.Salvia japonica Thunb. toil is put down, clearing away heat-damp and promoting diuresis, promoting blood flow to regulate menstruation, removing toxic substances and promoting subsidence of swelling; 3 careless toil temperature of gold, promoting the circulation of QI to relieve pain, dispelling cold by warming the meridian; Radix Astragali invigorating QI to consolidate the body surface resistance, diuresis poison holding, granulation promoting; Radix Et Caulis Acanthopanacis Senticosi replenishing kidney, strengthening waist, benefiting vital QI for tranquillizing, promoting blood circulation to remove obstruction in the collateral, four medicines are adjuvant drug.All medicines close 5, are use mutually, have expelling wind and removing dampness, promoting blood circulation to remove blood stasis, heat-clearing and toxic substances removing, the effect of blood nourishing acupuncture-stimulating, take a tonic or nourishing food to build up one's health Liver and kidney, solid protection taste, treating both the principal and secondary aspects of a disease simultaneously.
The pharmaceutical research present situation of the present invention's each medical material used is as described below.
Salvia japonica Thunb.: [nature and flavor] bitter in the mouth; Pungent; Property is put down.[function cures mainly] clearing away heat-damp and promoting diuresis; Promoting blood flow to regulate menstruation; Removing toxic substances and promoting subsidence of swelling.Main jaundice; Red white dysentery; Damp-heat vaginal discharge; Menoxenia; Dysmenorrhea; Skin infection furuncle and phyma; Traumatic injury.[usage and dosage] takes orally: decoct soup, 15-30g.
3 gold grass: [nature and flavor] are bitter, micro-pungent, temperature.[function cures mainly] promoting the circulation of QI to relieve pain, dispelling cold by warming the meridian, removing toxic substances.For heatstroke stomachache, colicky, menoxenia, dysmenorrhea, puerperal arthralgia, rabies.[usage and dosage] 3 ~ 5 money (fresh careless 0.5 ~ 1 liang).Suitable amount used externally, fresh grass is a little with Sal, mashes deposited affected part.
The Radix Astragali: [nature and flavor] are sweet, temperature.[return through] returns lung, spleen channel.[function cures mainly] invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, expelling pus and promoting granulation.Weak for the deficiency of vital energy, anorexia and loose stool, sinking of QI of middle-JIAO, chronic diarrhea proctoptosis, metrorrhagia of having blood in stool, exterior deficiency spontaneous perspiration, deficiency of vital energy edema, carbuncle difficulty is burst, and burst for a long time and do not hold back, blood deficiency dull yellowish colored skin, interior-heat is quenched one's thirst; Chronic nephritis proteinuria, diabetes.[usage and dosage] 9 ~ 30g.
Radix Et Caulis Acanthopanacis Senticosi: [nature and flavor] pungent, micro-hardship, temperature.[return through] returns spleen, kidney, heart channel.[function cures mainly] replenishing QI to invigorate the spleen, tonifying the kidney for tranquilization.For deficiency of spleen-YANG and kidneyYANG, body void is weak, inappetence, soreness of waist and knee joint, insomnia and dreamful sleep.[usage and dosage] 9 ~ 27g.
Caulis Mucunae Wangii: [nature and flavor] are bitter, temperature.[function cures mainly] bone and muscle strengthening, menstruation regulating blood nourishing medicinal.Cure mainly poliomyelitis sequela, anemia, menoxenia, bones and muscles pain due to rheumatism.
Radix cynanchi wilfordii: [nature and flavor] sweet in the mouth; Micro-hardship; Slightly warm in nature; [return through] spleen; Stomach; Kidney channel.[function cures mainly] invigorating the liver and kidney; Bone and muscle strengthening; Strengthening the spleen and stomach; Removing toxic substances.Main Liver and kidney two is empty; Feel dizzy; Insomnia forgetfulness; Early whitening of beard and hair; Sexual impotence; Seminal emission; The acid of waist knee joint is climbed; Spleen insufficiency; Distension and fullness in the abdomen; Ren is for depressed; Have loose bowels; Puerperal, breast was few; Lymphogranuloma inguinale sore.[usage and dosage] takes orally: decoct soup, 9-15g external: fresh goods is appropriate, smashes deposited.
Radix Lespedezae Tomentosae: [nature and flavor] are sweet; Micro-light; Property is put down.[return through] spleen channel.[function cures mainly] spleen invigorating tonify deficiency; Clearing away heat-damp and promoting diuresis; Promoting blood flow to regulate menstruation.Main asthenia; Blood deficiency is dizzy; Edema; Ascites; Dysentery; Amenorrhea; Dysmenorrhea.[usage and dosage] takes orally: decoct soup.
Radix Seu Caulis Mucunae Sempervirentis: [nature and flavor] are bitter; Micro-hardship; Warm in nature.[return through] liver; Stomach warp.[function cures mainly] promoting blood flow to regulate menstruation; To enrich blood relaxing muscles and tendons.Main have through uncomfortable; Dysmenorrhea; Amenorrhea; Puerperal blood deficiency; Anemia; Rheumatic arthralgia; Numb limbs and tense tendons; Traumatic injury.[usage and dosage] takes orally: decoct soup, 15-30g, or infusing drugs in wine.External: appropriate, smashes deposited.
Salvia japonica Thunb.: [nature and flavor] bitter in the mouth; Pungent; Property is put down.[function cures mainly] clearing away heat-damp and promoting diuresis; Promoting blood flow to regulate menstruation; Removing toxic substances and promoting subsidence of swelling.Main jaundice; Red white dysentery; Damp-heat vaginal discharge; Menoxenia; Dysmenorrhea; Skin infection furuncle and phyma; Traumatic injury.[usage and dosage] takes orally: decoct soup.
Herba Laggerae Alatae: [nature and flavor] acrid in the mouth; Bitter; Slightly warm in nature.[function cures mainly] dispels the wind, and dehumidifying, changes stagnant, dissipating blood stasis, detumescence, removing toxic substances.Main cold, fever; Cough due to lung-heat; Rheumatic arthritis; Diarrhoea; Oedema due to nephritis; Amenorrhea; Traumatic injury; Furuncle carbuncle; Scrofula; Venom; Eczema pruritus.[usage and dosage] takes orally: decoct soup, 9-15g, fresh person 30-60g; Or smash juice clothes.External: appropriate, smashes deposited; Or decoct washing.
Herba Cyperi Iriae: [nature and flavor] acrid in the mouth; Slightly warm in nature.[return through] Liver Channel.[function cures mainly] expelling wind and removing dampness; Promoting blood flow to regulate menstruation.Main air wets bones and muscles pain; Paralysis; Menoxenia; Amenorrhea; Educate through; Traumatic injury.[usage and dosage] takes orally: decoct soup, 10-30g; Or infusing drugs in wine.
Present invention also offers the preparation method of described pharmaceutical preparation, the method mainly comprises the steps: that getting gold grass, Salvia japonica Thunb., Herba Laggerae Alatae, Herba Cyperi Iriaes at 3 pulverizes, add 3 gold grass, Salvia japonica Thunb., Herba Laggerae Alatae, Herba Cyperi Iriae weight 4-6 65% alcoholic solution extraction secondary doubly, each 1.5 hours, extracting solution reclaims after ethanol and is concentrated into extractum, dry, be ground into fine powder, get Radix Et Caulis Acanthopanacis Senticosi, Caulis Mucunae Wangii, Radix cynanchi wilfordii, the Radix Astragali, Radix Lespedezae Tomentosae, Radix Seu Caulis Mucunae Sempervirentis and 3 gold grass, Salvia japonica Thunb., Herba Laggerae Alatae, filtering residue after Herba Cyperi Iriae alcoholic solution extracts, add 5-8 times of weight parts water to soak, decoct extraction 2 times, each 1.5-2.0 hour (timing from during boiling), merge decoction liquor, relative density 1.05-1.10 when being concentrated into 60 DEG C, adding ethanol makes alcohol content be 40%, leave standstill after 24 hours, discard lower sediment thing, obtain supernatant, extractum is concentrated into after reclaiming ethanol, extract dry, be ground into fine powder, by gained fine powder mix homogeneously, directly be used as medicine to use or add appropriate amount of auxiliary materials through normal process steps and make clinical acceptable dosage form.As the peroral dosage form of the solid dosage form such as conventional tablet, dispersible tablet, effervescent tablet, chewable tablet, capsule, granule, pill, powder can be made, the peroral dosage form of the liquid forms such as syrup, oral liquid, decoction also can be made.
The peroral dosage form of pharmaceutical preparation further preferably of the present invention is tablet, capsule or granule, most preferably is capsule.
The present invention relatively and prior art, has following clear superiority:
Known by the zoopery embodiment 9 of pharmaceutical preparation of the present invention: the degree of inflammation that pharmaceutical preparation Pyrogentisinic Acid rubber cement of the present invention causes chronic pelvic inflammatory disease rat uterus has certain inhibitory action, compare with sham operated rats, the dirty body ratio in model group rats uterus significantly increases, and difference has statistical significance (P < 0.01); Compare with model group, the dirty body ratio of pharmaceutical preparation capsule of the present invention big or middle dosage group rat uterus has significance to decline, and difference has statistical significance (P < 0.01).
Hypomenorrhea can be significantly improved with the clinical cure rate of Patients with Pelvic Inflammatory Disease and obvious effective rate compared with matched group by the known pharmaceutical preparation observation group of the present invention of clinical observation experiment embodiment 10; Have better late result, and the clinical symptoms of patient not easily recurs, untoward reaction is few.
In a word, selected by pharmaceutical preparation of the present invention, medical material compatibility is suitable, meets Chinese medicine and pharmacy and modern medicine theory, comprehensively, medication is thoughtful in legislation, plays special effect, play expelling wind and removing dampness altogether, promoting blood circulation to remove blood stasis, heat-clearing and toxic substances removing, the effect of blood nourishing acupuncture-stimulating, take a tonic or nourishing food to build up one's health Liver and kidney simultaneously, solid protection taste, treating both the principal and secondary aspects of a disease, has unique effect to hypomenorrhea companion Patients with Pelvic Inflammatory Disease; Traditional Chinese medicine preparation of the present invention has Mutiple Targets, too many levels, multi-level comprehensive regulation effect, and side effect is less, and patient compliance is better, taking convenience, can effectively alleviate patient's burden and misery, the object for the treatment of both the principal and secondary aspects of a disease can be reached, wide popularization and application on clinic.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, the change carried out the present invention, combination or replacement, be apparent for a person skilled in the art, and be included within the scope of the present invention.
Embodiment 1 capsule
Prescription: 3 golden grass 20 parts, the Radix Astragali 12 parts, Radix Et Caulis Acanthopanacis Senticosi 12 parts, Caulis Mucunae Wangii 28 parts, Radix cynanchi wilfordii 15 parts, Radix Lespedezae Tomentosae 25 parts, Radix Seu Caulis Mucunae Sempervirentis 25 parts, Salvia japonica Thunb. 30 parts, Herba Laggerae Alatae 18 parts, Herba Cyperi Iriaes 26 parts.
Preparation method: get gold grass, Salvia japonica Thunb., Herba Laggerae Alatae, Herba Cyperi Iriaes at 3 and pulverize, add 3 gold grass, Salvia japonica Thunb., Herba Laggerae Alatae, Herba Cyperi Iriae weight 4-6 65% alcoholic solution extraction secondary doubly, each 1.5 hours, extracting solution reclaimed after ethanol and is concentrated into extractum, dry, be ground into fine powder, get Radix Et Caulis Acanthopanacis Senticosi, Caulis Mucunae Wangii, Radix cynanchi wilfordii, the Radix Astragali, Radix Lespedezae Tomentosae, Radix Seu Caulis Mucunae Sempervirentis and 3 gold grass, Salvia japonica Thunb., Herba Laggerae Alatae, filtering residue after Herba Cyperi Iriae alcoholic solution extracts, add 5-8 times of weight parts water to soak, decoct extraction 2 times, each 1.5-2.0 hour (timing from during boiling), merge decoction liquor, relative density 1.05-1.10 when being concentrated into 60 DEG C, adding ethanol makes alcohol content be 40%, leave standstill after 24 hours, discard lower sediment thing, obtain supernatant, extractum is concentrated into after reclaiming ethanol, extract dry, be ground into fine powder, by gained fine powder mix homogeneously, capsule is made through normal process steps.
The present embodiment capsule every is containing crude drug 2.1g.
Embodiment 2 capsule
Prescription: 3 golden grass 17 parts, the Radix Astragali 10 parts, Radix Et Caulis Acanthopanacis Senticosi 15 parts, Caulis Mucunae Wangii 30 parts, Radix cynanchi wilfordii 10 parts, Radix Lespedezae Tomentosae 20 parts, Radix Seu Caulis Mucunae Sempervirentis 30 parts, Salvia japonica Thunb. 20 parts, Herba Laggerae Alatae 18 parts, Herba Cyperi Iriaes 25 parts.
Preparation method: with reference to embodiment 1.
Embodiment 3 capsule
Prescription: 3 golden grass 22 parts, the Radix Astragali 13 parts, Radix Et Caulis Acanthopanacis Senticosi 11 parts, Caulis Mucunae Wangii 26 parts, Radix cynanchi wilfordii 17 parts, Radix Lespedezae Tomentosae 30 parts, Radix Seu Caulis Mucunae Sempervirentis 23 parts, Salvia japonica Thunb. 32 parts, Herba Laggerae Alatae 20 parts, Herba Cyperi Iriaes 25 parts.
Preparation method: with reference to embodiment 1.
Embodiment 4 capsule
Prescription: 3 golden grass 25 parts, the Radix Astragali 12 parts, Radix Et Caulis Acanthopanacis Senticosi 18 parts, Caulis Mucunae Wangii 30 parts, Radix cynanchi wilfordii 20 parts, Radix Lespedezae Tomentosae 15 parts, Radix Seu Caulis Mucunae Sempervirentis 28 parts, Salvia japonica Thunb. 24 parts, Herba Laggerae Alatae 19 parts, Herba Cyperi Iriaes 28 parts.
Preparation method: with reference to embodiment 1.
Embodiment 5 capsule
Prescription: 3 golden grass 23 parts, the Radix Astragali 10 parts, Radix Et Caulis Acanthopanacis Senticosi 18 parts, Caulis Mucunae Wangii 26 parts, Radix cynanchi wilfordii 16 parts, Radix Lespedezae Tomentosae 35 parts, Radix Seu Caulis Mucunae Sempervirentis 26 parts, Salvia japonica Thunb. 30 parts, Herba Laggerae Alatae 23 parts, Herba Cyperi Iriaes 30 parts.
Preparation method: with reference to embodiment 1.
Embodiment 6 capsule
Prescription: 3 golden grass 22 parts, the Radix Astragali 14 parts, Radix Et Caulis Acanthopanacis Senticosi 16 parts, Caulis Mucunae Wangii 32 parts, Radix cynanchi wilfordii 16 parts, Radix Lespedezae Tomentosae 28 parts, Radix Seu Caulis Mucunae Sempervirentis 22 parts, Salvia japonica Thunb. 34 parts, Herba Laggerae Alatae 16 parts, Herba Cyperi Iriaes 32 parts.
Preparation method: with reference to embodiment 1.
Embodiment 7 tablet
Prescription: 3 golden grass 18 parts, the Radix Astragali 12 parts, Radix Et Caulis Acanthopanacis Senticosi 14 parts, Caulis Mucunae Wangii 26 parts, Radix cynanchi wilfordii 16 parts, Radix Lespedezae Tomentosae 28 parts, Radix Seu Caulis Mucunae Sempervirentis 22 parts, Salvia japonica Thunb. 32 parts, Herba Laggerae Alatae 22 parts, Herba Cyperi Iriaes 28 parts.
Preparation method: get gold grass, Salvia japonica Thunb., Herba Laggerae Alatae, Herba Cyperi Iriaes at 3 and pulverize, add 3 gold grass, Salvia japonica Thunb., Herba Laggerae Alatae, Herba Cyperi Iriae weight 4-6 65% alcoholic solution extraction secondary doubly, each 1.5 hours, extracting solution reclaimed after ethanol and is concentrated into extractum, dry, be ground into fine powder, get Radix Et Caulis Acanthopanacis Senticosi, Caulis Mucunae Wangii, Radix cynanchi wilfordii, the Radix Astragali, Radix Lespedezae Tomentosae, Radix Seu Caulis Mucunae Sempervirentis and 3 gold grass, Salvia japonica Thunb., Herba Laggerae Alatae, filtering residue after Herba Cyperi Iriae alcoholic solution extracts, add 5-8 times of weight parts water to soak, decoct extraction 2 times, each 1.5-2.0 hour (timing from during boiling), merge decoction liquor, relative density 1.05-1.10 when being concentrated into 60 DEG C, adding ethanol makes alcohol content be 40%, leave standstill after 24 hours, discard lower sediment thing, obtain supernatant, extractum is concentrated into after reclaiming ethanol, extract dry, be ground into fine powder, by gained fine powder mix homogeneously, tablet is made through normal process steps.
Embodiment 8 granule
Prescription: 3 golden grass 20 parts, the Radix Astragali 15 parts, Radix Et Caulis Acanthopanacis Senticosi 10 parts, Caulis Mucunae Wangii 34 parts, Radix cynanchi wilfordii 20 parts, Radix Lespedezae Tomentosae 26 parts, Radix Seu Caulis Mucunae Sempervirentis 26 parts, Salvia japonica Thunb. 34 parts, Herba Laggerae Alatae 22 parts, Herba Cyperi Iriaes 30 parts.
Preparation method: get gold grass, Salvia japonica Thunb., Herba Laggerae Alatae, Herba Cyperi Iriaes at 3 and pulverize, add 3 gold grass, Salvia japonica Thunb., Herba Laggerae Alatae, Herba Cyperi Iriae weight 4-6 65% alcoholic solution extraction secondary doubly, each 1.5 hours, extracting solution reclaimed after ethanol and is concentrated into extractum, dry, be ground into fine powder, get Radix Et Caulis Acanthopanacis Senticosi, Caulis Mucunae Wangii, Radix cynanchi wilfordii, the Radix Astragali, Radix Lespedezae Tomentosae, Radix Seu Caulis Mucunae Sempervirentis and 3 gold grass, Salvia japonica Thunb., Herba Laggerae Alatae, filtering residue after Herba Cyperi Iriae alcoholic solution extracts, add 5-8 times of weight parts water to soak, decoct extraction 2 times, each 1.5-2.0 hour (timing from during boiling), merge decoction liquor, relative density 1.05-1.10 when being concentrated into 60 DEG C, adding ethanol makes alcohol content be 40%, leave standstill after 24 hours, discard lower sediment thing, obtain supernatant, extractum is concentrated into after reclaiming ethanol, extract dry, be ground into fine powder, by gained fine powder mix homogeneously, granule is made through normal process steps.
Embodiment 9 animal experiment: pharmaceutical preparation Pyrogentisinic Acid rubber cement of the present invention causes the impact of pelvic inflammatory disease rat model
1 data and method
1.1 experimental animals: SD rat, female, unpregnancy, cleaning grade, body weight 200-220g, is purchased from Beijing Vital River Experimental Animals Technology Co., Ltd..
1.2 medicines and reagent: traditional Chinese medicine fine powder prepared by the embodiment of the present invention 1; Estradiol benzoate injection, hydrocortisone injection; Hydroxybenzene mucilage (phenol, glycerol, tragcanth form, and concentration is decided to be 25%).
After the female non-pregnant rat adaptability of the preparation of 1.3 rat chronic pelvic inflammatory disease models: SD raises 3d, within the 4th day, rats by intraperitoneal injection 10% chloral hydrate 0.4mL/100g anaesthetizes, and lies on the back and is fixed on operating board, and hair is shaved, routine disinfection in abdomen center.Under aseptic condition, hypogastric region median incision is about 2cm, expose uterus, with No. 4 syringe needles at uterus crotch towards ovary direction inserting needle, wherein 40 are slowly injected 25% Hydroxybenzene mucilage 0.06mL.All the other 10 injection normal saline, as Sham-operated control group, successively close abdomen, sterilization art district.Postoperative routine raises 14d.
1.4 grouping and administrations: it is Post operation the 15th day that modeling completes, except Sham-operated control group, all the other modeling rats are divided into 4 groups at random, namely model control group, pharmaceutical preparation of the present invention high, medium and low dosage group (8.4g/kg, 4.2g/kg, 1.1g/kg) respectively organize continuous gastric infusion 14d by above-mentioned shown dosage, Sham-operated control group and model control group give isopyknic distilled water, and gavage volume is 20mL/kg.
1.5 observation index: after last administration 24h, weigh in, by rat with 10% chloral hydrate anesthesia, win bilateral uterine, with scales/electronic balance weighing after removing fatty tissue, be placed in formalin and fix, routine paraffin wax embeds, and HE dyes, basis of microscopic observation.
1.6 data analysiss: all data, all through the process of SPSS15.0 statistical software, adopting variance analysis, adopting t to check, with P < 0.05 for there being statistical significance between group.
2 results
2.1 pharmaceutical preparatioies of the present invention are on the impact of the dirty body ratio of rat body weight and uterus: after administration 14d, compare with sham operated rats, and the dirty body ratio in model group rats uterus significantly increases, and difference has statistical significance (P < 0.01); Compare with model group, the dirty body ratio of pharmaceutical preparation capsule of the present invention big or middle dosage group rat uterus has significance to decline, difference has statistical significance (P < 0.01), and the degree of inflammation of pointing out pharmaceutical preparation Pyrogentisinic Acid rubber cement of the present invention to cause chronic pelvic inflammatory disease rat uterus has certain inhibitory action.In table 1.
Table 1 pharmaceutical preparation of the present invention is on the impact of the dirty body ratio of rat model rat body weight and uterus
Note: compare with sham operated rats,
aap < 0.01; Compare with model control group,
bp < 0.05,
bbp < 0.01.
The change of 2.2 rat uterus anatomical morphologies and tectology: perusal, uterus color, the hardness of sham operated rats are normal, and swelling, hyperemia are seen in serosal surface end; The part uterus darker in color of model control group is red, serosal surface obvious tumefaction, hyperemia, and pelvic adhesion appears in individual animal; Compared with model control group, the swelling of each administration group rat uterus, hyperemia etc. have and alleviate in various degree, and high dose group endometrial epithelial cell has no hypertrophy, lamina propria mild inflammatory cellular infiltration; The slight hypertrophy of middle dosage group endometrial epithelial cell, lamina propria moderate inflammatory cellular infiltration; Low dose group endometrial epithelial cell moderate hypertrophy, lamina propria moderate inflammatory cellular infiltration, points out pharmaceutical preparation of the present invention to pelvic inflammatory disease rat model by certain therapeutical effect.
Embodiment 10 clinical observation is tested
1 data and method
1.1 physical data: observe in January, 2014 to a 2014 year December and go to a doctor in my institute's Out-patient Clinic of Department of Gynecology, are diagnosed as patient 112 example that hypomenorrhea card suffers from chronic pelvic inflammatory disease simultaneously, are divided into observation group and matched group to observe at random, often organize 56 routine.Observation group's age 18-to 34-year-old, 24.2 ± 3.8 years old mean age, matched group age 18-33 year, average 24.7 ± 4.1 years old; Observation group's course of disease is the longest 4.5 years, the shortest 6 months, and average 1.45 ± 0.78 years, the matched group course of disease was the longest 4.5 years, the shortest 5 months, average 1.56 ± 0.91 years; Observation group has 47 routine patients to have abortion history, and matched group has 45 routine patients to have abortion history.Two groups of physical data compare no difference of science of statistics (P > 0.05), have comparability.
1.2 diagnostic criterias: the diagnostic criteria of writing the hypomenorrhea of " guideline of clinical investigations of new Chinese medicine treatment menoxenia " of " Gynecology of Chinese Medicine " and Ministry of Health of the People's Republic of China promulgation in 2002 according to Zhang Yuzhen etc.
Hypomenorrhea: hypomenorrhea refers to that menstrual cycle is normal, and menstrual blood loss comparatively constant obviously reduces, and even drop is namely clean, or through line time less than 2 days, through the menopathy that amount is also few.
1.3 exclusion standards: have cryptorrhea, luteal phase defect; There are the Chronic consumptions persons such as hyperthyroidism, tuberculosis, severe anemia; There is oral hormone in 3 months, use contraceptive person; Untoward reaction person is there is in drug administration process; Not by regulation medication, cannot judge that curative effect or data are not congruent and affect the treatment or statistical disposition person.
1.4 Therapeutic Method:
Observation group: the capsule that menstruation brings into use the embodiment of the present invention 1 to prepare on the 5th day, each 2-4 grain, every day 2 times, was a course for the treatment of with 3 months, takes 3 months continuously.
Matched group: use Western medicine capable artificial cycle estrogen and progestogen sequential therapy, take FUKE QIANJIN PIAN, every day three times, each 2-4 grain simultaneously.
1.5 observation index: adverse effect during observing the therapeutic effect of two groups of patients and medication; Treatment is followed up a case by regular visits to after terminating rear third time menstrual onset, and record related symptoms is observed.
1.6 statistical methods: adopt SPSS15.0 statistical software to calculate.Each numerical value with
represent, measurement data adopts t inspection, and enumeration data adopts χ
2inspection, with P < 0.05 for difference has statistical significance.
2 results
2.1 criterions of therapeutical effect: according to " guideline of clinical investigations of new Chinese medicine treatment menoxenia ", draft following criterion of therapeutical effect: recovery from illness: treat rear menstrual cycle, recover normal through amount, other transference cures, drug withdrawal 3 non-recidivists of menstrual cycle.Effective: menstrual blood volume increases by 1/3, and other transference cures alleviate, and drug withdrawal 3 menstrual cycle are without recidivist.Effective: treat rear menstrual cycle, through amount, comparatively treat front improvement menstrual period, other symptoms alleviate before comparatively treating.Invalid: treatment after menstrual cycle, through amount and menstrual period without improvement.
2.2 observation of curative effect
2.2.1 two groups of patient's comparitive study: observation group's recovery from illness 22 example, effective 20 examples, effective 13 examples, invalid 1 example, obvious effective rate 75.0%, total effective rate 98.2%; Matched group recovery from illness 13 example, effective 16 examples, effective 17 examples, invalid 10 examples, obvious effective rate 51.8%, total effective rate 82.1%, observation group compares with matched group obvious effective rate, total effective rate, difference has statistical significance (P < 0.05), illustrates that clinical cure rate and the obvious effective rate of hypomenorrhea significantly can improve compared with matched group in observation group.In table 2.
Table 2 liang group patient comparitive study (n%, example)
Note: compare with matched group, * P < 0.05.
2.2.2 after two groups of treatments, Follow-up results compares
Time after treatment is finished to effective follow-up of patients, in the routine patient of observation group 42, there is 1 routine patient when following up a case by regular visits to, hypomenorrhea, and in the routine patient of matched group 29, have 10 routine patient menstrual very few, 2 routine patient's amenorrheas, illustrate that the patient of matched group clinical symptoms after drug withdrawal has bounce-back.Can illustrate that observation group compares with matched group and has better late result accordingly, and the clinical symptoms of patient not easily recurs, also demonstrate the disease that pharmaceutical preparation of the present invention can treat hypomenorrhea companion pelvic inflammatory disease, make body obtain good recovery.
2.2.3 the observation of adverse effect during medication: have 1 routine patient to occur slight gastrointestinal reaction during observation group's patient medication.18 routine patients are had to occur slight gastrointestinal reaction during matched group patient medication, as Nausea and vomiting, upper abdomen dull pain; Have 3 routine patients to occur irregular colporrhagia, observation group compares with matched group, and difference has statistical significance, and observation group's less adverse effect, patient compliance is better.
Therapeutic outcome shows: observation group can significantly improve hypomenorrhea with the clinical cure rate of Patients with Pelvic Inflammatory Disease and obvious effective rate compared with matched group; Have better late result, and the clinical symptoms of patient not easily recurs, untoward reaction is few, is one pharmaceutical preparation safely and effectively, for Chinese medicine hypomenorrhea provides new method, is worth studying and applying further.
Claims (10)
1. treat a pharmaceutical preparation for hypomenorrhea companion pelvic inflammatory disease, it is characterized in that by gold grass, the Radix Astragali, Radix Et Caulis Acanthopanacis Senticosi, Caulis Mucunae Wangii, Radix cynanchi wilfordii, Radix Lespedezae Tomentosae, Radix Seu Caulis Mucunae Sempervirentis, Salvia japonica Thunb., Herba Laggerae Alatae, Herba Cyperi Iriaes be that medicinal raw material is made at 3.
2. the pharmaceutical preparation for the treatment of hypomenorrhea companion pelvic inflammatory disease as claimed in claim 1, is characterized in that being made up of the medicinal raw material of following weight: 3 careless 15-25 parts of gold, Radix Astragali 5-15 part, Radix Et Caulis Acanthopanacis Senticosi 8-18 part, Caulis Mucunae Wangii 16-36 part, Radix cynanchi wilfordii 10-20 part, Radix Lespedezae Tomentosae 15-35 part, Radix Seu Caulis Mucunae Sempervirentis 18-36 part, Salvia japonica Thunb. 20-40 part, Herba Laggerae Alatae 15-25 part, Herba Cyperi Iriae 20-40 part.
3. the pharmaceutical preparation for the treatment of hypomenorrhea companion pelvic inflammatory disease as claimed in claim 2, is characterized in that being made up of the medicinal raw material of following weight: 3 careless 17-23 parts of gold, Radix Astragali 8-13 part, Radix Et Caulis Acanthopanacis Senticosi 11-15 part, Caulis Mucunae Wangii 26-32 part, Radix cynanchi wilfordii 12-17 part, Radix Lespedezae Tomentosae 24-30 part, Radix Seu Caulis Mucunae Sempervirentis 20-26 part, Salvia japonica Thunb. 26-34 part, Herba Laggerae Alatae 18-23 part, Herba Cyperi Iriae 25-30 part.
4. the pharmaceutical preparation for the treatment of hypomenorrhea companion pelvic inflammatory disease as claimed in claim 3, is characterized in that being made up of the medicinal raw material of following weight: 3 golden grass 20 parts, the Radix Astragali 12 parts, Radix Et Caulis Acanthopanacis Senticosi 12 parts, Caulis Mucunae Wangii 28 parts, Radix cynanchi wilfordii 15 parts, Radix Lespedezae Tomentosae 25 parts, Radix Seu Caulis Mucunae Sempervirentis 25 parts, Salvia japonica Thunb. 30 parts, Herba Laggerae Alatae 18 parts, Herba Cyperi Iriaes 26 parts.
5. the pharmaceutical preparation of the treatment hypomenorrhea companion pelvic inflammatory disease as described in claim 1-4, it is characterized in that preparation method comprises the steps: that getting gold grass, Salvia japonica Thunb., Herba Laggerae Alatae, Herba Cyperi Iriaes at 3 pulverizes, add 3 gold grass, Salvia japonica Thunb., Herba Laggerae Alatae, Herba Cyperi Iriae weight 4-6 65% alcoholic solution extraction secondary doubly, each 1.5 hours, extracting solution reclaims after ethanol and is concentrated into extractum, dry, be ground into fine powder, get Radix Et Caulis Acanthopanacis Senticosi, Caulis Mucunae Wangii, Radix cynanchi wilfordii, the Radix Astragali, Radix Lespedezae Tomentosae, Radix Seu Caulis Mucunae Sempervirentis and 3 gold grass, Salvia japonica Thunb., Herba Laggerae Alatae, filtering residue after Herba Cyperi Iriae alcoholic solution extracts, add 5-8 times of weight parts water to soak, decoct extraction 2 times, each 1.5-2.0 hour (timing from during boiling), merge decoction liquor, relative density 1.05-1.10 when being concentrated into 60 DEG C, adding ethanol makes alcohol content be 40%, leave standstill after 24 hours, discard lower sediment thing, obtain supernatant, extractum is concentrated into after reclaiming ethanol, extract dry, be ground into fine powder, by gained fine powder mix homogeneously, directly be used as medicine to use or add appropriate amount of auxiliary materials through normal process steps and make clinical acceptable dosage form.
6. the pharmaceutical preparation of the treatment hypomenorrhea companion pelvic inflammatory disease as described in claim 1-4, is characterized in that described pharmaceutical preparation is peroral dosage form.
7. the pharmaceutical preparation for the treatment of hypomenorrhea companion pelvic inflammatory disease as claimed in claim 6, is characterized in that described peroral dosage form is preferably tablet, dispersible tablet, effervescent tablet, chewable tablet, capsule, granule, pill, powder, syrup, oral liquid, decoction etc.
8. the pharmaceutical preparation for the treatment of hypomenorrhea companion pelvic inflammatory disease as claimed in claim 7, is characterized in that described peroral dosage form is preferably tablet, capsule, granule.
9. the pharmaceutical preparation for the treatment of hypomenorrhea companion pelvic inflammatory disease as claimed in claim 8, is characterized in that described peroral dosage form is preferably capsule.
10. the purposes of the pharmaceutical preparation described in claim 1-4 in the medicine of preparation treatment hypomenorrhea companion pelvic inflammatory disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610045938.4A CN105477251A (en) | 2016-01-25 | 2016-01-25 | Pharmaceutic preparation for treating hypomenorrhea with pelvic inflammation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610045938.4A CN105477251A (en) | 2016-01-25 | 2016-01-25 | Pharmaceutic preparation for treating hypomenorrhea with pelvic inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105477251A true CN105477251A (en) | 2016-04-13 |
Family
ID=55664765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610045938.4A Withdrawn CN105477251A (en) | 2016-01-25 | 2016-01-25 | Pharmaceutic preparation for treating hypomenorrhea with pelvic inflammation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105477251A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085273A (en) * | 2007-06-26 | 2007-12-12 | 北京艺信堂医药研究所 | Traditional Chinese medicine composition for curing hypomenorrhea |
| CN101085317A (en) * | 2007-06-26 | 2007-12-12 | 北京艺信堂医药研究所 | Chinese patent medicine for treating hypomenorrhea |
| CN102018853A (en) * | 2009-09-23 | 2011-04-20 | 栗素琴 | Traditional Chinese medicine preparation for treating oligomenorrhea |
-
2016
- 2016-01-25 CN CN201610045938.4A patent/CN105477251A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085273A (en) * | 2007-06-26 | 2007-12-12 | 北京艺信堂医药研究所 | Traditional Chinese medicine composition for curing hypomenorrhea |
| CN101085317A (en) * | 2007-06-26 | 2007-12-12 | 北京艺信堂医药研究所 | Chinese patent medicine for treating hypomenorrhea |
| CN102018853A (en) * | 2009-09-23 | 2011-04-20 | 栗素琴 | Traditional Chinese medicine preparation for treating oligomenorrhea |
Non-Patent Citations (1)
| Title |
|---|
| 付素洁等: "《中医妇科学》", 31 January 2010, 中国中医药出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520654B (en) | A kind of Chinese medicine composition being used for the treatment of knee osteoarthritis and preparation method thereof | |
| CN102342992B (en) | Chinese medicinal composition for treating insomnia and preparation method of preparation thereof | |
| CN104352776B (en) | A kind of hypomenorrhia for the treatment of causes infertile Chinese medicine preparation and preparation method thereof | |
| CN102836409B (en) | Traditional Chinese medicine for treating postpartum lochiorrhea and preparation method | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN103536838B (en) | A kind of Chinese medicine preparation for the treatment of threatened abortion and preparation method thereof | |
| CN103341092A (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN101607067B (en) | Traditional Chinese medicine preparation for treating cholelithiasis and preparation method thereof | |
| CN103330837B (en) | Traditional Chinese medicine composition for curing osteoporosis of menopausal women | |
| CN103157062B (en) | Medicine composition curing gynaecological mass diseases such as fibroids and preparation method and application thereof | |
| CN103041306B (en) | Traditional Chinese medicine composition for curing climacteric syndrome of women and preparation method thereof | |
| CN102274417A (en) | Chinese patent medicament for treating aplastic anemia | |
| CN102048913B (en) | Traditional Chinese medicine preparation for treating climacteric syndrome and preparation method thereof | |
| CN103301353A (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN103735792B (en) | A kind of medicine for the treatment of menoxenia and preparation method thereof | |
| CN105749167A (en) | Traditional Chinese medicine composition for treating amenorrhea | |
| CN105902951A (en) | Traditional Chinese medicinal compound for treating osteosarcomas on basis of chemotherapeutic drugs | |
| CN103301373A (en) | Pharmaceutical composition for treating postpartum perineal mucosal lesions | |
| CN105477251A (en) | Pharmaceutic preparation for treating hypomenorrhea with pelvic inflammation | |
| CN102697955A (en) | Medicine for treating gynecological diseases | |
| CN103316270B (en) | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion | |
| CN105250634A (en) | Traditional Chinese medicine composition for treating postpartum constipation and application thereof | |
| CN105727237A (en) | Folium artemisiae argyi-containing pharmaceutical composition for treating amenorrhea | |
| CN104435734A (en) | Traditional Chinese medicine preparation for nursing uterine leiomyoma and preparation method of traditional Chinese medicine preparation | |
| CN104940777A (en) | Electuary capable of treating liver-yang hyperactivity and spleen weakness type diarrhea during menstruation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160413 |